Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer

British Journal of Cancer

Volumn 104, Issue 10, 2011, Pages 1594-1601

  Takezawa, K ^a   Okamoto, I ^a   Okamoto, W ^a   Takeda, M ^a   Sakai, K ^a   Tsukioka, S ^b   Kuwata, K ^a   Yamaguchi, H ^a   Nishio, K ^a   Nakagawa, K ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

apoptosis; immunohistochemistry; non small cell lung cancer; pemetrexed; thymidylate synthase

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; PEMETREXED; THYMIDYLATE SYNTHASE;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS INHIBITION; DRUG EFFECT; DRUG RESPONSE; DRUG SCREENING; DRUG SENSITIVITY; ENZYME ACTIVITY; GENE INDUCTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; GLUTAMATES; GUANINE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; RETROSPECTIVE STUDIES; THYMIDYLATE SYNTHASE;

EID: 79955813242     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.129     Document Type: Article

References (20)

1. Carreras CW, Santi DV (1995) The catalytic mechanism and structure of thymidylate synthase. Annu Rev Biochem 64: 721-762
2. Ceppi P, Volante M, Saviozzi S, Rapa I, Novello S, Cambieri A, Lo Iacono M, Cappia S, Papotti M, Scagliotti GV (2006) Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 107: 1589-1596 (Pubitemid 44546920)
3. Ferguson PJ, Collins O, Dean NM, DeMoor J, Li CS, Vincent MD, Koropatnick J (1999) Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells. Br J Pharmacol 127: 1777-1786 (Pubitemid 29392871)
4. Giovannetti E, Lemos C, Tekle C, Smid K, Nannizzi S, Rodriguez JA, Ricciardi S, Danesi R, Giaccone G, Peters GJ (2008) Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Mol Pharmacol 73: 1290-1300 (Pubitemid 351439211)
5. Gomez HL, Santillana SL, Vallejos CS, Velarde R, Sanchez J, Wang X, Bauer NL, Hockett RD, Chen VJ, Niyikiza C, Hanauske AR (2006) A phase II trial of pemetrexed in advanced breast cancer: clinical response and association with molecular target expression. Clin Cancer Res 12: 832-838 (Pubitemid 43259865)
6. Hoffman PC, Mauer AM, Vokes EE (2000) Lung cancer. Lancet 355: 479-485 (Pubitemid 30085163)
7. Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC, Chabner BA, Allegra CJ (1994) The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12: 2640-2647 (Pubitemid 24379651)
8. Johnston PG, Mick R, Recant W, Behan KA, Dolan ME, Ratain MJ, Beckmann E, Weichselbaum RR, Allegra CJ, Vokes EE (1997) Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. J Natl Cancer Inst 89: 308-313 (Pubitemid 27085893)
9. Monica V, Scagliotti GV, Ceppi P, Righi L, Cambieri A, Lo Iacono M, Saviozzi S, Volante M, Novello S, Papotti M (2009) Differential thymidylate synthase expression in different variants of large-cell carcinoma of the lung. Clin Cancer Res 15: 7547-7552
10. Okamoto W, Okamoto I, Tanaka K, Hatashita E, Yamada Y, Kuwata K, Yamaguchi H, Arao T, Nishio K, Fukuoka M, Janne PA, Nakagawa K (2010) TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation. Mol Cancer Ther 9: 2785-2792
11. Ozasa H, Oguri T, Uemura T, Miyazaki M, Maeno K, Sato S, Ueda R (2010) Significance of thymidylate synthase for resistance to pemetrexed in lung cancer. Cancer Sci 101: 161-166
12. Pestalozzi BC, Peterson HF, Gelber RD, Goldhirsch A, Gusterson BA, Trihia H, Lindtner J, Cortes-Funes H, Simmoncini E, Byrne MJ, Golouh R, Rudenstam CM, Castiglione-Gertsch M, Allegra CJ, Johnston PG (1997) Prognostic importance of thymidylate synthase expression in early breast cancer. J Clin Oncol 15: 1923-1931 (Pubitemid 27209522)
13. Righi L, Papotti MG, Ceppi P, Bille A, Bacillo E, Molinaro L, Ruffini E, Scagliotti GV, Selvaggi G (2010) Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J Clin Oncol 28: 1534-1539
14. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26: 3543-3551
15. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98 (Pubitemid 34438899)
16. Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, Shackelford KA, Mendelsohn LG, Soose DJ, Patel VF, Andis SL, Bewley JR, Rayl EA, Moroson BA, Beardsley GP, Kohler W, Ratnam M, Schultz RM (1997) LY231514, a pyrrolo[2,3-d]pyrimidine-based anti-folate that inhibits multiple folate-requiring enzymes. Cancer Res 57: 1116-1123 (Pubitemid 27138611)
17. Sigmond J, Backus HH, Wouters D, Temmink OH, Jansen G, Peters GJ (2003) Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol 66: 431-438 (Pubitemid 36937028)
18. Takeda M, Okamoto I, Hirabayashi N, Kitano M, Nakagawa K (2010) Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer. Lung Cancer; doi:10.1016/ j.lungcan.2010.10.022
19. Takezawa K, Okamoto I, Tsukioka S, Uchida J, Kiniwa M, Fukuoka M, Nakagawa K (2010) Identification of thymidylate synthase as a potential therapeutic target for lung cancer. Br J Cancer 103: 354-361
20. Uramoto H, Onitsuka T, Shimokawa H, Hanagiri T (2010) TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed. Anticancer Res 30: 4309-4315